The Race-Based Drug Race

| November-December 2007

Some ethnic groups suffer particular ailments at higher rates—think of Tay-Sachs disease among Ashkenazi Jews or sickle-cell anemia among those from sub-Saharan Africa—so it’s natural that pharmaceutical companies might investigate drugs that could help particular populations. But GeneWatch (May/June 2007) reports that something else might be behind some firms’ efforts to get race-specific patents for their products: an extended period of monopolistic control. Take NitroMed’s BiDil, a drug approved by the Food and Drug Administration in June 2005 for treatment of heart failure in African Americans. The drug, much ballyhooed as the first approved for use in a specific racial or ethnic group, had previously been patented for use in the general population. That original patent, also held by the Massachusetts-based company, expires in 2007. The new race-specific patent holds until 2020, adding 13 years to NitroMed’s monopoly over the drug’s market, even though experts disagree on whether BiDil works any better for African Americans than it does for everyone else.

Pay Now Save $5!

Utne Summer 2016Want to gain a fresh perspective? Read stories that matter? Feel optimistic about the future? It's all here! Utne Reader offers provocative writing from diverse perspectives, insightful analysis of art and media, down-to-earth news and in-depth coverage of eye-opening issues that affect your life.

Save Even More Money By Paying NOW!

Pay now with a credit card and take advantage of our earth-friendly automatic renewal savings plan. You save an additional $5 and get 4 issues of Utne Reader for only $40.00 (USA only).

Or Bill Me Later and pay just $45 for 4 issues of Utne Reader!

Facebook Instagram Twitter

click me